AstraZeneca Pharma India Limited (ASTRAZEN)
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
Press Release - Q1FY27
- Total revenue from operations 6.83bn INR +30% y-y; PAT 507mn INR
- Growth driven by Oncology (+26%), Biopharmaceuticals (+36%), Rare Diseases (+35x) in Q1 FY27
- Regulatory approvals received for acalabrutinib and trastuzumab deruxtecan in key indications
- Strategic initiatives include AI-enabled lung cancer screening MoU with Telangana and pan-India hyperkalaemia management program
- Recognized with Medical Excellence and Employee Experience awards in 2026
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 ASTRAZEN — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add ASTRAZEN to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on AstraZeneca Pharma India Limited
Important.
The summary above is generated automatically from AstraZeneca Pharma India Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.